Sun Pharmaceutical Industries received approval from South Africa's health regulator to manufacture and sell a generic version of semaglutide [1, 2].
This development could significantly lower the cost of treatment for type-2 diabetes and obesity in the region. By introducing a generic alternative to Novo Nordisk’s Ozempic and Wegovy, the move aims to increase patient access to critical weight-loss and glucose-regulating medication [1, 2].
The South African Health Products Regulatory Authority, known as SAHPRA, granted the nod to the Indian drugmaker [1, 2]. Semaglutide is the active ingredient used in the high-demand medications produced by Novo Nordisk [1, 3]. The approval allows Sun Pharma to establish local production and distribution channels within South Africa [1, 2].
Sun Pharma is expanding its global footprint following previous success with the drug in India [1, 2]. The company intends to leverage this regulatory win to provide a more affordable option for patients who cannot access the branded versions of the medication [1, 2].
Local manufacturing is expected to reduce reliance on expensive imports and stabilize the supply chain for semaglutide injections [3]. This strategy aligns with broader efforts to improve healthcare affordability in the country, a priority for the national health system [1, 2].
The announcement regarding the regulatory approval occurred on July 15, 2024 [2].
“Sun Pharma received approval from South Africa's health regulator to manufacture and sell a generic version of semaglutide.”
The entry of a generic semaglutide into the South African market signals a shift toward breaking the monopoly of high-cost GLP-1 receptor agonists. As demand for obesity and diabetes medications surges globally, local production in South Africa reduces logistics costs and price barriers, potentially setting a precedent for other emerging markets to challenge the pricing power of major pharmaceutical firms like Novo Nordisk.
